Red Tree Management, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002055980

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024

Q3 2026 · 3 positions · Total reported value $116.71M · Top-10 concentration 100.0% · Updated 2026-10-16

Last updated: 2026-10-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Red Tree Management, LLC disclosed 3 equity positions with a combined reported value of $116.71M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were BCAX ($54.35M), CBLL ($53.80M), CTNM ($8.56M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Red Tree Management, LLC opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Red Tree Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Red Tree Management, LLC is an SEC-registered 13F filer. As of Q3 2026 it reported 3 US equity positions with a combined value of $116.71M. HoldingsHub carries 8 quarters of its filings (Q4 2024–Q3 2026).

Portfolio Structure

  • 3 positions · $116.71M reported value (Q3 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: BCAX (BICARA THERAPEUTICS INC) at 46.6%
  • Average position size: $38.90M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 1 reduced
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund's activity suggests a conservative stance with a slight lean towards health care. The reduction in the BCAX position and holding steady on the CBLL and CTNM positions indicates a preference for stability in a volatile market. 2. Key Moves: - BCAX (BICARA THERAPEUTICS INC): Reduced by 7.7% from 3,163,517 to 2,920,509 shares, possibly due to concerns about the company's prospects or market conditions. - CBLL (CERIBELL INC): Held steady, with no change in share count, suggesting confidence in the company's prospects and the sector's overall stability. - CTNM (CONTINEUM THERAPEUTICS INC CL): Held steady as well, indicating a commitment to the health care sector. 3. Portfolio Structure: - Passive/Active: The fund appears to be more passive, with a focus on holding steady in existing positions rather than actively trading. - Sector Bias: The fund has a significant bias towards the health care sector, which is evident from the three out of ten holdings being in this sector. - Risk Appetite: The risk appetite is conservative, as reflected in the reduction in the BCAX position and the decision to hold steady on the other positions. 4. Per-Holding One-Liner: - BCAX (BICARA THERAPEUTICS INC): Developing novel therapies for neurological disorders; 'unverified' - CBLL (CERIBELL INC): Focused on the development of therapies for rare genetic neurological diseases; 'unverified' - CTNM (CONTINEUM THERAPEUTICS INC CL): A biopharmaceutical company focusing on therapies for chronic liver disease; 'unverified' 5. One-Sentence Style Summary: Red Tree Management maintained a conservative approach in the third quarter of 2026, focusing on stability within the health care sector while cautiously trimming exposure to BICARA THERAPEUTICS INC.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.92M $54.35M 46.57%
46.57%
Reduce
2 2.21M $53.80M 46.09%
46.09%
Hold
3 638.16K $8.56M 7.34%
7.34%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 100% R 100% F1 100% (modelled on 2026-Q2; 3/10 hit)

Historical Backtest (6 quarters)

Avg precision 96% · recall 100% · F1 98% · avg rank error 0.4 · Top-10 turnover 4%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2025-Q2 75% 100% 86% CBLL · BCAX · CTNM · CRGX CBLL · BCAX · CTNM
2025-Q3 100% 100% 100% CBLL · BCAX · CTNM BCAX · CBLL · CTNM
2025-Q4 100% 100% 100% BCAX · CBLL · CTNM BCAX · CBLL · CTNM
2026-Q1 100% 100% 100% BCAX · CBLL · CTNM BCAX · CBLL · CTNM
2026-Q2 100% 100% 100% BCAX · CBLL · CTNM BCAX · CBLL · CTNM
2026-Q3 ★ 100% 100% 100% BCAX · CBLL · CTNM BCAX · CBLL · CTNM

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Red Tree Management, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Red Tree Management, LLC reported 3 equity positions worth $116.71M in aggregate; its largest disclosed positions were BCAX ($54.35M), CBLL ($53.80M), CTNM ($8.56M).

How large is Red Tree Management, LLC's portfolio?

Red Tree Management, LLC reported $116.71M of long equity holdings across 3 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is Red Tree Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/red-tree-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →